Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial

Lancet Rheumatol, 2025 DOI 10.1016/S2665-9913(25)00022-0


LinkedIn